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Experimental and clinical evidence suggests that 16 -hydroxy-
lated estrogen metabolites, biologically strong estrogens, are
associated with breast cancer risk, while 2-hydroxylated me-
tabolites, with lower estrogenic activity, are weakly related to
this disease. This study analyzes the association of breast cancer
risk with estrogen metabolism, expressed as the ratio of 2-hy-
droxyestrone to 16 -hydroxyestrone, in a prospective nested
case-control study. Between 1987 and 1992, 10,786 women
(ages 35–69 years) were recruited to a prospective study on
breast cancer in Italy, the “Hormones and Diet in the Etiology
of Breast Cancer” (ORDET) study. Women with a history of
cancer and women on hormone therapy were excluded at
baseline. At recruitment, overnight urine was collected from
all participants and stored at  80°C. After an average of 5.5
years of follow-up, 144 breast cancer cases and four matched
controls for each case were identified among the participants of
the cohort. Among premenopausal women, a higher ratio of
2-hydroxyestrone to 16 -hydroxyestrone at baseline was asso-
ciated with a reduced risk of breast cancer: women in the
highest quintile of the ratio had an adjusted odds ratio (OR)
for breast cancer of 0.58 [95% confidence interval (CI)  
0.25 1.34]. The corresponding adjusted OR in postmeno-
pausal women was 1.29 (95% CI   0.53–3.10). Results of this
prospective study support the hypothesis that the estrogen
metabolism pathway favoring 2-hydroxylation over 16 -hy-
droxylation is associated with a reduced risk of invasive breast
cancer risk in premenopausal women. (Epidemiology 2000;11:
635–640)
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In 1979, Thomas Dao postulated that the way in which
estrogens are metabolized might be important for breast
cancer development.1 The theory, known as “the uncon-
ventional estrogen hypothesis,” proposed that the prod-
ucts of estrogen metabolism may be of etiological signif-
icance.1 The theory originated from the evidence that
“conventional” estrogens accounted only for less than
half of total circulating estrogens1 and from the incon-
sistent results observed, at that time, in epidemiologic
studies based on “conventional” estrogen determina-
tions. In 1982, Bradlow et al. hypothesized that hydroxy-
lation of estradiol at the C-2 position produces metab-
olites with little or no estrogenic activity and thus it
might be associated with decreased breast cancer risk.
Conversely, hydroxylation of estradiol at the C-16 po-
sition produces metabolites with high estrogenic activ-
ity, and might be associated with increased breast cancer
risk.2 Several experimental, clinical, and epidemiologic
studies support this hypothesis. In in vitro studies, 16 -
hydroxylation has been shown to have strong biological
estrogenic activity3–5 and genotoxic characteristics,6
while 2-hydroxylation metabolites had virtually no pe-
ripheral estrogenic effects.7 In mice, 16 -hydroxylation
of estrone was associated with increased spontaneous
incidence of mammary tumors.8 In clinical studies, the
extent of biotransformation of radiolabeled E2 via the
16 -hydroxylation pathway was higher in breast tissue
(terminal duct lobular unit) from patients with breast
cancer than it was for tissue from women who had
undergone reductive mammoplasty.9 In general, epide-
miologic studies on estrogen metabolism support the
proposed hypothesis. In case-control studies an increase
in estrone 16 -hydroxylation in breast cancer cases was
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635observed compared with healthy controls, in particular
in postmenopausal women.2,10–13 In other case-control
studies, however, little or no association was found in
premenopausal,14 or in postmenopausal women.15 Until
now, only one prospective study has been conducted to
investigate the role of estrogen metabolism as predictor
of breast cancer. In that study, participants in the high-
est tertile of the 2-hydroxyestrone/16 -hydroxyestrone
ratio had a 40% reduction in breast cancer risk com-
pared with those in the lowest tertile.16
The present report analyzes the association between
invasive breast cancer (ductal and lobular carcinoma)
and prediagnostic estrogen metabolism. In particular, we
tested the hypothesis that the pathway favoring 2-hy-
droxylation over 16 -hydroxylation may be associated
with a decrease in breast cancer risk.
Methods
Between June 1987 and June 1992, 10,786 healthy women,
ages 35 to 69 years, residents of Varese province, northern
Italy, participated in a prospective study of hormones, diet,
andbreastcancerrisk:the“OrmoniEDietaNellaEtiologia
DeiTumoriDellaMammella”(ORDET)study.17Allmem-
bers of the cohort were volunteers recruited from the gen-
eral population through radio, television, and newspaper
advertising. Women were also invited to participate in the
study through meetings organized by municipalities, local
offices of the Italian National Health System, women’s
associations, churches, and unions. There were 162,700
women between 35 and 69 years of age (the age-range of
the cohort study)18 in Varese province during the recruit-
ment phase of the study. Thus, the total number of women
recruited in the cohort represents approximately 7% of the
general population of women in that age range.
Women with a history of cancer and bilateral oopho-
rectomy, and those currently pregnant or breast feeding,
with chronic or acute liver disease, or on hormone
therapy within 3 months before recruitment into the
study were not eligible to participate. At baseline, ques-
tionnaires on menstrual history and reproductive char-
acteristics, and data on height, weight, and other an-
thropometric measures were collected. Anthropometric
measurements were made by nurses based on a standard-
ized protocol. We calculated body mass index (BMI) as
weight in kilograms divided by height in meters squared.
Postmenopausal status was defined as the absence of
menstrual bleeding for at least 12 months.
CASE ASCERTAINMENT
On June 1995, after an average of 5.5 years of follow-up,
the ORDET file was linked with the local cancer registry
(Lombardy Cancer Registry) files to identify breast cancer
cases. The ORDET file was also linked with the regional
file of Varese residents to determine the vital status of the
cohortmembers.Thirty-sevenwomenwerediagnosedwith
breast cancer before enrollment in the cohort, four were
diagnosed with breast cancer in situ, and 10 were lost to
follow-up. Thus, there were 10,735 women eligible for this
study. Among those, 89 died from causes other than breast
cancer and 144 were identified by the cancer registry as
cases of invasive breast cancer; of them 71 were postmeno-
pausal at the time of recruitment.
CONTROLS
For each breast cancer case, four matched controls were
randomly chosen from members of the cohort who were
alive at the time of diagnosis of the matched case with-
out having developed breast cancer. Controls were
matched to cases on age ( 5 years), menopausal status,
time of day at blood draw (each participant donated 40
ml of whole blood), recruitment center (participants
were recruited in two centers, 25 km apart, and speci-
mens collected in the second center were transported by
car every morning to the laboratory located in the first
center), and recruitment date ( 180 days).
SAMPLE COLLECTION
All women participating in the study were asked to
urinate before bedtime (7:00 PM) and then to collect all
overnight urine including the first-morning urine (7:00
AM) in a standard container provided by the study. At
the completion of the urine collection, samples were
transported to the laboratory of the study center. Within
3 hours after the last void, urine samples were filtered
and stored in freezers at  80°C. Urine containers were
tightly capped to prevent evaporation. Urine was not
removed from the freezers, and the temperature was kept
constant throughout storage, with no freeze-thaw cycles.
In premenopausal women, urine was collected in the
luteal phase of the menstrual cycle between the 20th and
the 24th day.
Estrogen metabolism was compared in cases and in
controls using the ratio of 2:16 -hydroxyestrone. An
increase in 2-hydroxylation (or a decrease in 16 -hy-
droxylation), reflected by a high ratio value, was inter-
preted as a shift of estrogen metabolism toward a less
estrogenic hormonal milieu.
LABORATORY ANALYSIS
Stored urinary samples from breast cancer cases and
related controls were handled identically and assayed
together in the same batch. All laboratory personnel
were blinded with regard to case-control status.
Analyses of 2-hydroxyestrone (2-OHE1) and 16 -
hydroxyestrone (16 -OHE1) were performed using a
competitive solid-phase enzyme immunoassay (IMMUNA
CARE Corporation, Bethlehem, PA).19 The urinary
forms of these estrogen metabolites are found as gluc-
uronide conjugates and require the removal of the sugar
moiety before recognition by the monoclonal antibodies.
A mixture of  -glucuronidase and arylsulfatase (glusu-
lase from Helix pomatia, Sigma Chemical Co., St. Louis,
MO) was used for this purpose. The enzyme digest was
then neutralized. Assay incubation time was 3 hours at
room temperature. The assay was read kinetically using a
Ceres 900 HDI plate reader (Biotek Instruments, Wi-
nooski, VT), and the data were reduced using Kineticalc
EIA Application software (Bio-Tek® Instruments). Both
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of metabolites with serial dilution and “spiking” of ex-
ogenous estrogens into urine samples. The EIA kits have
been evaluated for validity and reproducibility and the
values for each metabolite were compared with values
obtained by gas chromatography-mass spectrometry.19–24
As a measure of reproducibility, control samples were
included and their values had to fall within two standard
deviations from the mean of a continuous Levy-Jennings
control plot. In addition, 10% duplicates were included
with each batch of samples to determine reproducibility.
The within-assay coefficient of variation was 6% for
samples at the urinary concentration levels for premeno-
pausal women, and 13% for levels characteristic of post-
menopausal women.
STATISTICAL ANALYSIS
2-hydroxyestrone and 16 -hydroxyestrone urinary levels
were standardized by the total volume of urine collec-
tion. We used conditional logistic regression to obtain
the odds ratios of breast cancer in relation to estrogen
metabolites and their ratio.25 The independent variables
of interest were 2-OHE1, 16 -OHE1, and the ratio of
2-OHE1 and 16 -OHE1 by quintiles of serum concen-
tration. We based the cutoff points for each quintile on
the distribution of the estrogen metabolites in controls.
Premenopausal women had approximately fourfold
higher urinary 2-OHE1 and 16 -OHE1 than postmeno-
pausal women (median of 40.3 ng/ml for 2-OHE1 and
17.5 ng/ml for 16 -OHE1 in premenopausal and 9.7
ng/ml and 4 ng/ml in postmenopausal women). Because
of these differences in estrogen metabolite levels in
urine, premenopausal and postmenopausal women were
analyzed separately.
There were 73 eligible premenopausal breast cancer
cases and 292 matched controls. We excluded six breast
cancer cases and the 24 related controls because they
were perimenopausal [mean age of 51, with a maximum
of two menstrual bleedings in the year before recruit-
ment into the study, with estrogen metabolite levels
lower than premenopausal, and higher than postmeno-
pausal women (median of 26.85 ng/ml for 2-OHE1, and
8.38 ng/ml for 16 -OHE1)]. In addition, we excluded
four controls because of missing urine collection. Finally,
67 premenopausal breast cancer cases and 264 controls
were available for the present analysis. In postmeno-
pausal women, there were 71 breast cancer cases and 284
matched controls. We excluded 10 controls because of
missing urine collection; the final analysis included 71
breast cancer cases and 274 controls.
We identified age, BMI, waist-to-hip ratio, age at men-
arche, age at first birth, parity, and age at menopause as
TABLE 1. Characteristics of the Study Participants
Premenopause Postmenopause
Cases Controls Cases Controls
N % N % N % N %
Age (yrs) Age (yrs)
35–41 23 34.3 72 27.1 43–55 16 22.5 66 24
42–45 10 14.9 74 28.4 56–58 21 29.6 79 29
46–48 16 23.9 66 24.9 59–62 12 16.9 58 21.2
49–57 18 26.9 52 19.6 63–70 22 31.0 71 25.8
BMI (kg/m2) BMI (kg/m2)
 21.5 15 22.3 67 25.2  23.8 22 31.0 63 23.1
21.6–24.0 17 25.4 67 25.2 23.9–26.0 15 21.2 72 26.2
24.1–27.8 17 25.4 65 24.8 26.01–29.0 17 23.9 69 25.1
 27.8 18 26.9 65 24.8  29.0 17 23.9 70 25.6
Waist-to-hip ratio Waist-to-hip ratio
 0.74 14 20.9 72 27.4  0.77 21 29.6 59 21.4
0.75–0.78 12 17.9 73 27.9 0.78–0.81 16 22.5 65 23.8
0.79–0.81 19 28.4 51 19.1 0.82–0.85 15 21.2 78 28.4
 0.81 22 32.8 68 25.6  0.85 19 26.7 72 26.4
Menarche (yrs) Menarche (yrs)
 12 13 19.4 56 21.2  12 10 14.1 37 13.4
12 15 22.4 62 23.5 12 13 18.3 47 16.9
13 23 34.3 56 21.2 13 15 21.1 59 21.5
 14 16 23.9 90 34.1  14 33 46.5 131 47.2
Age at 1st birth (yrs) Age at 1st birth (yrs)
 22 19 32.2 56 23.6  23 18 29.5 76 30.8
23–24 12 20.4 60 25.3 24 6 9.9 25 10.1
25–27 10 16.9 63 26.6 25–27 21 34.3 78 31.6
 28 18 30.5 58 24.5  28 16 26.3 68 27.5
Parity Parity
0 8 11.9 28 10.6 0 7 9.9 35 12.8
1 15 22.4 53 20.1 1 22 31.0 56 20.4
2 32 47.8 128 48.5 2 26 36.6 102 37.3
 3 12 17.9 55 20.8  3 16 22.5 81 29.5
Menopause (yrs)
 46 17 23.9 84 30.6
47–48 18 25.4 67 24.5
49–52 24 33.8 72 26.3
 53 12 16.9 51 18.6
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relevance and logistic regression was used to control for
these covariates. In the initial regression model, we exam-
ined all variables. We evaluated each covariate for con-
founding by removing each from the fully adjusted model.
Age, BMI, waist-to-hip ratio, age at menarche, age at first
birth, parity, and age at menopause did not substantially
modify the results. None of the potential covariates was a
confounder of the association between breast cancer and
estrogen metabolites and their ratio. Nevertheless, we in-
cluded them in further analysis to provide fully adjusted
estimates for comparison with those reported in the pub-
lished literature, in particular with the previous prospective
cohort study.16
As last step of the analysis, we investigated the shape of
the dose-response relation of estrogen metabolism, re-
flected by the 2-OHE1/16 -OHE1 ratio, and breast cancer
risk using spline regression estimates in premenopausal and
postmenopausal women. We included age, BMI, waist-to-
hip, and reproductive variables in the model as parametric
covariates (just as in the logistic model), while the
2-OHE1/16 -OHE1ratiowasincludedasatermsmoothed
by a smoothing spline. The fitted odds ratio from this
model for each person was plotted as a function of the
estrogen metabolite ratio. We used the median of the
lowest quintile of the 2-OHE1/16 -
OHE1 ratio as a reference.
Results
Characteristics of the study population
are reported in Table 1. Among pre-
menopausal women, cases were more
likely to have higher BMI, and a
higher waist-to-hip ratio, and to report
an earlier age at menarche, later age at
first full-term pregnancy, and nullipar-
ity. For postmenopausal women, cases
were similar to controls in age at men-
arche, and age at first full-term preg-
nancy. Cases reported lower number of
children and older age at menopause
and presented lower BMI, and waist-
to-hip ratio.
In premenopausal women, the crude
and the adjusted estimates for 2-OHE1
and for 16 -OHE1 were slightly
higher than in postmenopausal women
(Tables 2 and 3). Within each group
of women, the risk ratio levels for both
estrogen metabolites were similar,
with wide confidence intervals. In pre-
menopausal women (Table 2), the in-
crease in 2-OHE1/16 -OHE1 ratio
was associated with a reduction in
odds ratios for breast cancer across
quintiles: the highest quintile of
2-OHE1/16 -OHE1 ratio had the
lowest risk estimate, even after adjust-
ment for covariates.
Figure 1 shows the ORs for breast cancer as a function
of the 2-OHE1/16 -OHE1 ratio estimated by smoothed
regression splines. The ORs of breast cancer decreased
with increases in the estrogen metabolites ratio.
In postmenopausal women (Table 3), there was no
clear evidence of decreased breast cancer risk with in-
creasing levels of 2-OHE1/16 -OHE1 ratio. In Figure 2,
the plot of ORs, as a function of 2-OHE1/16 -OHE1
ratio, indicates that there was an increase in breast
cancer risk in the second, third, and fourth quintile of
2-OHE1/16 -OHE1 ratio and a tendency toward a de-
crease in risk in the fifth quintile of the ratio.
Discussion
Results of this prospective nested case-control study
suggest that the estrogen metabolism pathway favoring
2-hydroxylation over 16 -hydroxylation is associated
with a reduced risk of invasive breast cancer risk, in
particular in premenopausal women. In postmenopausal
women, the association of estrogen metabolites and their
ratio with breast cancer risk was weaker and the risk
reduction was not evident.
There are a number of potential explanations for these
findings, including physiological differences between pre-
TABLE 2. Breast Cancer Risk by Quintiles of Estrogen Metabolite Levels and
Their Ratio in Premenopausal Women
Cases/Controls Crude RR
Adjusted
RR*
2-hydroxyestrone (2-OHE1)
I† 9/53 1.00 1.00
II 15/52 1.70 1.83
(0.68–4.22) (0.73–4.60)
III 18/54 1.96 2.08
(0.81–4.75) (0.85–5.09)
IV 15/53 1.67 1.85
(0.67–4.14) (0.73–4.66)
V 10/52 1.13 1.23
(0.43–3.01) (0.45–3.35)
16 -hydroxyestrone (16 -OHE1)
I† 7/52 1.00 1.00
II 18/54 2.48 2.52
(0.96–6.42) (0.97–6.58)
III 13/52 1.86 2.01
(0.69–5.03) (0.74–5.52)
IV 17/53 2.38 2.62
(0.91–6.22) (0.99–6.96)
V 12/53 1.68 1.90
(0.61–4.61) (0.68–5.31)
2-OHE1/16 -OHE1 Ratio
I† 19/54 1.00 1.00
II 14/51 0.78 0.76
(0.35–1.72) (0.34–1.69)
III 11/52 0.60 0.60
(0.26–1.39) (0.25–1.44)
IV 12/54 0.63 0.62
(0.28–1.43) (0.27–1.45)
V 11/53 0.59 0.55
(0.26–1.36) (0.23–1.32)
* ORs-adjusted for age, body mass index, waist-to-hip, and reproductive variables.
† Referent category.
Quintile definition for 2-OHE1: I,  18.94 ng/ml; II, 18.94–32.90 ng/ml; III, 32.90–53.91 ng/ml; IV,
53.91–86.88 ng/ml; V,  86.88 ng/ml.
Quintile definition for 16 -OHE1: I,  7.95 ng/ml; II, 7.95–14.51 ng/ml; III, 14.51–21.58 ng/ml; IV,
21.58–36.35 ng/ml; V,  36.35 ng/ml.
Quintile definition for 2-OHE1/16 -OHE1 Ratio: I,  1.80; II, 1.80–2.30; III, 2.30–2.72; IV, 2.72–3.29;
V,  3.29.
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effect of estrogen metabolism on breast cancer risk. We can
speculate that in women with the highest levels of biolog-
ically active estrogens, characteristic of premenopausal
women, the weaker activity of 2-OHE1 may prevail in
protecting target tissues from the action of the major active
estrogens (2-OHE1 estrogen antagonist action). Con-
versely, in postmenopausal women with low estrogen con-
centration, estrogens with weak biological activity may
support epithelial cell proliferation and neoplastic transfor-
mation (2-OHE1 estrogen agonist action).
Furthermore, reasons for the observed discrepancy be-
tween premenopausal and postmenopausal women may be
related to exposure to breast cancer risk factors occurring
after urine collection in postmenopausal women character-
ized by lower 2OHE1/16 -OHE1 ratio, such as increase in
body weight or initiation of hormone replacement therapy.
Unfortunately, up-dated information on exposure to breast
cancer risk factors after recruitment is presently not avail-
able to support this interpretation of the study results.
Finally, the lack of association of estrogen metabolism and
breast cancer risk in postmenopausal women, might also be
explained, at least in part, by the high technical variability
of estrogen metabolite determinations observed in urine
from this group of women. Postmenopausal women are
characterized by fourfold lower urine es-
trogen metabolite levels than premeno-
pausal women. At postmenopausal es-
trogen metabolite levels, we observed
larger laboratory variability than at the
level detected in premenopausal women
(coefficients of variation were 13% and
6%, respectively). Biochemical analyses
were conducted in blind fashion, and
since the distribution of urinary levels of
estrogen metabolites and their ratio was
similar for breast cancer cases and re-
lated controls, the errors in hormone
measurements were likely to be ran-
domly distributed between breast cancer
cases and controls resulting in an atten-
uation of the point estimates, in partic-
ular in postmenopausal women.26
Intra-individual variability and the
long-term effect of cryopreservation are
additional sources of variability in the
determination of estrogen metabolites
potentially affecting the study results. In
fact, the present study was based on one
single urine collection and data from a
previously published study27 showed that
2-hydroxyestrone and 16 -hy-
droxyestrone are characterized by a cer-
tain level of measurement error due to
intra-individual variability (intraclass
correlation coefficients were R   0.79
for 2-OHE1 and R   0.62 for 16 -
OHE1), which may contribute to the
attenuation of the observed risks. Sam-
ple degradation might be expected to
introduce a source of variability in prospective cohort stud-
ies; however, data from a previous prospective study
FIGURE 1. Premenopausal women: Spline curve of the
semi-parametric fit of the 2-OHE1/16 -OHE1 ratio after
adjustment for age, BMI, waist-to-hip ratio, and reproductive
variables with the 10th percentile of the 2-OHE1/16 -OHE1
ratio as reference. Quintiles of the ratio are indicated by the
letters Q1 to Q5.
TABLE 3. Breast Cancer Risk by Quintiles of Estrogen Metabolite Levels and
Their Ratio in Postmenopausal Women
Cases/Controls Crude RR
Adjusted
RR*
2-hydroxyestrone (2OHE1)
I† 10/54 1.00 1.00
II 20/55 1.96 1.77
(0.84–4.58) (0.75–4.20)
III 14/56 1.35 1.30
(0.55–3.30) (0.52–3.21)
IV 11/54 1.10 0.94
(0.43–2.80) (0.36–2.46)
V 16/55 1.57 1.61
(0.65–3.77) (0.66–3.94)
16 -hydroxyestrone (16 OHE1)
I† 11/53 1.00 1.00
II 17/57 1.44 1.35
(0.62–3.35) (0.57–3.18)
III 13/55 1.14 1.01
(0.47–2.77) (0.40–2.50)
IV 15/54 1.34 1.18
(0.56–3.18) (0.48–2.87)
V 15/55 1.31 1.34
(0.55–3.12) (0.55–3.27)
2OHE1/16 -OHE1 Ratio
I† 12/54 1.0 1.0
II 16/55 1.31 1.42
(0.56–3.02) (0.60–3.33)
III 17/54 1.42 1.41
(0.62–3.25) (0.60–3.33)
IV 12/57 0.95 1.02
(0.39–2.29) (0.41–2.53)
V 14/54 1.17 1.31
(0.49–2.75) (0.53–3.18)
* ORs-adjusted for age, BMI, waist-to-hip and reproductive variables.
† Referent category.
Quintile definition for 2OHE1: I,  4.32 ng/ml; II, 4.32–7.86 ng/ml; III, 7.86–12.77 ng/ml; IV, 12.77–
21.11 ng/ml; V,  21.11 ng/ml.
Quintile definition for 16 -OHE1: I,  1.81 ng/ml; II, 1.81–3.28 ng/ml; III, 3.28–5.08 ng/ml; IV,
5.08–8.15 ng/ml; V,  8.15 ng/ml.
Quintile definition for 2OHE1/16 -OHE1 Ratio: I,  1.77; II, 1.77–2.26; III, 2.26–2.80; IV, 2.80–3.66; V,
 3.66.
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thermore, cases and controls were matched on date at
sample collection. Thus, any degradation effect should be
minimal and similar for cases and controls.
The present results may also be compatible with a
potential role of estrogen metabolism as an indicator of
undiagnosed breast cancer rather than a precursor. The
40% decrease in breast cancer risk observed in our study
for the highest quintile of premenopausal women, how-
ever, was similar to the results of the Guernsey prospec-
tive study after 19 years of follow-up.16
The present prospective study and the previous one
differed in number of breast cancer cases in postmeno-
pausal status (42 in the Guernsey study vs 71 in the
ORDET study), and in the findings concerning post-
menopausal women: the Guernsey study found similar
results in premenopausal and in postmenopausal women.
Participants of the two prospective studies were similar
in age, BMI, and in the distribution of classical breast
cancer risk factors. The concordant findings, in partic-
ular among premenopausal women, are suggestive of an
effect of estrogen metabolism on breast cancer risk.
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